Greg Verdine’s LifeMine raises $263M for safer immunosuppressant

Positive

AI Analysis

Summary

LifeMine Therapeutics raised $263 million across two venture rounds, including a previously unannounced $75 million Series D, to advance development of a potentially safer and more convenient immunosuppressant for transplant patients.

Importance:6/10

Sentiment:

0.70

fundraisingventure capitalimmunosuppressanttransplantationLifeMine Therapeutics

Read the original article

Published by Endpoints News on August 6, 2026 10:30 AM

Read Original